Location · Washington D.C., DC
Clinical trials in Washington D.C., DC
221 recruiting studies have a site in Washington D.C., and 73 of them accept healthy volunteers.
221 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- Recruiting
Pediatric Percutaneous Ultrasound Gastrostomy Technique
CoapTech
- Location
- Washington D.C., DC + 2 other US sites
- Eligibility basics
- Ages 0 mo–21
- RecruitingPhase 2
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
PPD Development, LP
- Location
- Washington D.C., DC + 27 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
PPD Development, LP
- Location
- Washington D.C., DC + 27 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
PPD Development, LP
- Location
- Washington D.C., DC + 27 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
PPD Development, LP
- Location
- Washington D.C., DC + 26 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
- Location
- Washington D.C., DC + 47 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Healx Limited
- Location
- Washington D.C., DC + 13 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
- Location
- Washington D.C., DC + 21 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingPhase 2
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
Maze Therapeutics
- Location
- Washington D.C., DC + 58 other US sites
- Eligibility basics
- Ages 18–68
- RecruitingPhase 1/Phase 2
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Cartesian Therapeutics
- Location
- Washington D.C., DC + 2 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 3 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
Vericel Corporation
- Location
- Washington D.C., DC + 6 other US sites
- Eligibility basics
- Ages 17–65
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Washington D.C., DC + 69 other US sites
- Eligibility basics
- Ages 18–80
- Recruiting
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
Innova Vascular, Inc.
- Location
- Washington D.C., DC + 12 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
GRIN Therapeutics, Inc.
- Location
- Washington D.C., DC + 15 other US sites
- Eligibility basics
- Ages 1 mo–18
- RecruitingPhase 3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics
- Location
- Washington D.C., DC + 73 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
Medtronic Cardiovascular
- Location
- Washington D.C., DC + 27 other US sites
- Eligibility basics
- Ages 20+
- RecruitingPhase 3
A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery
Corza Medical GmbH
- Location
- Washington D.C., DC + 8 other US sites
- Eligibility basics
- Ages 1 mo+
- RecruitingPhase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
DalCor Pharmaceuticals
- Location
- Washington D.C., DC + 112 other US sites
- Eligibility basics
- Ages 45+
- Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Abbott Medical Devices
- Location
- Washington D.C., DC + 56 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Neurona Therapeutics
- Location
- Washington D.C., DC + 34 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
Rapamycin Holdings Inc.
- Location
- Washington D.C., DC + 17 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
BioMarin Pharmaceutical
- Location
- Washington D.C., DC + 30 other US sites
- Eligibility basics
- Ages 3–11
- RecruitingPhase 2
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.
- Location
- Washington D.C., DC + 19 other US sites
- Eligibility basics
- Ages 18+